Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05365061 · ClinicalTrials.gov registry record · NA

Periosteal Electrical Dry Needling for Knee Osteoarthritis

A NA study, sponsored by Alabama Physical Therapy & Acupuncture.

Completed
Registry status
NA
Development phase
586
Enrollment target

NCT05365061: Completed NA study, sponsored by Alabama Physical Therapy & Acupuncture.

NCT05365061 is a NA study that has completed, run by Alabama Physical Therapy & Acupuncture. The registered enrollment target is 586 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05365061, a NA study, has completed, sponsored by Alabama Physical Therapy & Acupuncture.

COMPLETED
Registry status
NA
Development phase
586 participants
Enrollment target

Study Summary

The purpose of this research is to treat patients with knee osteoarthritis (OA) with periosteal electric dry needling (PEDN). It is also to determine the optimal "maintenance" regiment (i.e. maintenance treatments, one maintenance treatment every other month, or one maintenance treatment per month) required to maintain improvements in pain and function following PEDN. Physical therapists commonly use PEDN to treat knee OA, and previous studies suggest that this treatment is useful for reducing pain and improving function in patients with osteoarthritis. However, an appropriate maintenance treatment strategy to maintain these outcomes is presently unknown.

Primary Outcome

24 questions each worth 0-4 points with maximum score of 96 points possible. The greater the score, the worse the symptoms of knee OA

Interventions

  • OTHER periosteal electrical dry needling with no maintenance treatments
  • OTHER periosteal electrical dry needling with maintenance treatments every other month
  • OTHER periosteal electrical dry needling with monthly maintenance treatments

Trial Details

FieldValue
Enrollment Target 586 participants
Start Date 2021-03-01
Est. Completion 2024-05-01
Phase NA

What the finished NCT05365061 record still lists

NCT05365061 is an interventional study that assigns participants to a tested intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 3 interventions - of which periosteal electrical dry needling with no maintenance treatments is the first listed.

NCT05365061 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05365061 about?

NCT05365061 is a clinical study titled "Periosteal Electrical Dry Needling for Knee Osteoarthritis". The purpose of this research is to treat patients with knee osteoarthritis (OA) with periosteal electric dry needling (PEDN). It is also to determine the optimal "maintenance" regiment (i.e. maintenance treatments, one maintenance treatment every other month, or one maintenance treatment per month) ...

What is the current status of trial NCT05365061?

This trial is currently completed. It is a NA study. The enrollment target is 586 participants. The study started on 2021-03-01. Estimated completion is 2024-05-01.

What interventions are being tested in trial NCT05365061?

The interventions under investigation include: periosteal electrical dry needling with no maintenance treatments (OTHER), periosteal electrical dry needling with maintenance treatments every other month (OTHER), periosteal electrical dry needling with monthly maintenance treatments (OTHER).

Who is sponsoring clinical trial NCT05365061?

This trial is sponsored by Alabama Physical Therapy & Acupuncture, which has 14 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05365061's enrollment target sits among peer trials

586 176th of 2000 higher than 1,825 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04134260 · 586 participants · Phase 3

    Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

  • NCT06100770 · 586 participants

    Aveir AR Coverage With Evidence Development (CED) Study

  • NCT06183281 · 586 participants · NA

    Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity

  • NCT06976203 · 586 participants · Phase 3

    A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05365061, the US trial registry maintained by the National Library of Medicine. NCT05365061 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.